VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial

Exclusion criteria

• . Patient has a known history of allergic sensitivities (including but not limited to cyanoacrylate adhesives), or any other condition, which in the opinion of the investigator may make the patient more susceptible to cyanoacrylate adhesive hypersensitivity
• . Patient has known deep vein obstruction in the target limb, as identified by the site's standard of care
• . Patient has abnormal pulse exam or ABI \<0.8
• . Patient has acute superficial thrombophlebitis
• . Patient requires any non-target vein treatments in the contralateral or ipsilateral limb, or any other surgical procedure up tp 30 days pre-procedure and through 3 months post-procedure
• . Patient has any co-morbid conditions, which in the investigator's opinion may interfere with the patient's compliance with study visits and procedures, or may confound interpretation of study data (e.g., congestive heart failure Class III and IV, non-ambulatory patients, severe hepatic dysfunction, life expectancy \< 1 year)
• . IFU contraindications:
• . Patient is non-ambulatory

Randomized Study VenaSeal™ System Versus Surgical Stripping: Primary Endpoint: Elimination of Clinically Relevant Superficial Truncal Disease in Each Target Vein at the Time of Index Procedure.

Timeframe: Post Index procedure, on the day of the procedure immediately following treatment